Neurogene Inc. (NGNE) Revenue by Segment & Business Profile
Gene therapies for rare neurological diseases was 100.0% of Neurogene Inc.'s revenue, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NGNENeurogene Inc.Follow NGNE — free
—
Price chart with a free account
- Market cap
- 471.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 17 days
What the company does
Neurogene Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $0 as of 2026-06-30.
Roles we read
from the filings, not the sector label- Clinical-stage developer
Neurogene Inc. — questions
- What does Neurogene Inc. do?
- Neurogene Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $0 as of 2026-06-30.
- How does Neurogene Inc. make money?
- By the lines it reports in its SEC filings: Gene therapies for rare neurological diseases 100.0% of revenue.
Every figure on this page comes from Neurogene Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.